Single dose piroxicam for acute postoperative pain

Area of Science:

• Pharmacology
• Pain Management
• Clinical Trials

Background:

• Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) used for rheumatic disorders.
• Direct comparisons between analgesics are limited, necessitating indirect comparisons via placebo-controlled trials.

Purpose of the Study:

• To evaluate the analgesic efficacy and adverse effects of single-dose piroxicam versus placebo in moderate to severe postoperative pain.
• To compare piroxicam's effects with other analgesics.

Main Methods:

• Systematic literature search of multiple databases (Medline, Embase, Cochrane Library, etc.).
• Inclusion of randomized, double-blind, placebo-controlled trials of oral or intramuscular piroxicam in adult patients with moderate to severe postoperative pain.
• Data extraction on pain relief and adverse effects, calculating number-needed-to-treat (NNT) and number-needed-to-harm (NNH).

Main Results:

• Piroxicam (20 mg and 40 mg) demonstrated significant analgesic efficacy compared to placebo.
• NNT for at least 50% pain relief was 2.7 for 20 mg and 1.9 for 40 mg piroxicam.
• Adverse effect incidence was similar between piroxicam and placebo groups.

Conclusions:

• Single-dose piroxicam is effective for moderate to severe postoperative pain.
• Piroxicam exhibits comparable efficacy to other NSAIDs and intramuscular morphine.
• Piroxicam presents a favorable safety profile with no increased adverse effects compared to placebo.